Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : FBN Associates: A Perfect Company -- Ignore unavailable to you. Want to Upgrade?

To: Bill Ulrich who wrote (1823)	7/19/1998 6:49:00 AM
From: Jeffrey S. Mitchell	Read Replies (3) \| Respond to of 2117

OK, let's turn over all the cards and expose the CYGS hype job. It's a pretty darn good one at that. If you follow biotech, you know that the big bucks are being gambled on various and sundry biological therapies (immunology). The hottest thing in biotherapy is a thing called a "vector". We've all heard of genes being discovered for this and that, right? Well, the big problem has always been in how you get those genes into the cell without destroying the cell. Once there, you can hopefully get that cell to replicate the injected DNA and thus create a killing factory targeted to whatever it is you are trying to cure. CYGS recently bought a vector. If you read their press releases carefully, you see they talk about other research done by other companies who have vectors intending to give one the impression that they can do the same thing (i.e. "independent studies have shown"). They then talk about all the wonderful things vectors can do, all of which are theoretically true, again trying to give the impression they can potentially do them. Notice how careful they are about saying things like "our research suggests" and "research continues", as opposed to something more scientific like "our in vitro studies have shown..." Several of you might recall the recent ENMD hysteria when the NY Times published a front page article about how their angiogenesis process cured cancer in mice. CYGS hasn't even cured a mouse from what I can see. And if they did, they'd still be years away from clinical trials, assuming they even have a single person on staff who could figure out how to make the leap from mouse to man... not an easy thing to do obviously. My guess is CYGS will announce in some vague terms that their research shows their patented vector could possibly be used to slow down the aging process. Just like DHEA created a frenzy when it supposedly did the same thing, CYGS hopes their perception as a biotech firm will create an even bigger media event. Who knows, they may be right. Here's an example of a company that's a legitimate player in the vector sweepstakes. Notice who posted on the thread and when (g). No, I have no position in the company; I'm just a closet biotech guy I guess (Though we joke about it, blastomere separation is a very real process used to clone cells!): Subject 21704 - Jeff